{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:21:28Z","timestamp":1791498088878,"version":"4.3.4"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s12016-014-8455-6","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T09:02:50Z","timestamp":1417510970000},"page":"307-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Use of Biologic Therapies in Uveitis"],"prefix":"10.1007","volume":"49","author":[{"given":"Sergio","family":"Schwartzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,29]]},"reference":[{"key":"8455_CR1","unstructured":"Levy-Clarke, G., et al., Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology, 2013."},{"issue":"5 Suppl 61","key":"8455_CR2","first-page":"S145","volume":"28","author":"A Ali","year":"2010","unstructured":"Ali A, Rosenbaum JT (2010) Use of methotrexate in patients with uveitis. Clin Exp Rheumatol 28(5 Suppl 61):S145\u2013S150","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"8455_CR3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1076\/ocii.11.2.131.15919","volume":"11","author":"A Kaplan-Messas","year":"2003","unstructured":"Kaplan-Messas A et al (2003) Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11(2):131\u2013139","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"8455_CR4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/09273940903137675","volume":"17","author":"CM Deuter","year":"2009","unstructured":"Deuter CM et al (2009) Mycophenolate sodium for immunosuppressive treatment in uveitis. Ocul Immunol Inflamm 17(6):415\u2013419","journal-title":"Ocul Immunol Inflamm"},{"key":"8455_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000336192","volume":"51","author":"DD Klisovic","year":"2012","unstructured":"Klisovic DD (2012) Mycophenolate mofetil use in the treatment of noninfectious uveitis. Dev Ophthalmol 51:57\u201362","journal-title":"Dev Ophthalmol"},{"issue":"12","key":"8455_CR6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/bjo.81.12.1107","volume":"81","author":"AD Dick","year":"1997","unstructured":"Dick AD, Azim M, Forrester JV (1997) Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 81(12):1107\u20131112","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"8455_CR7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/112067210701700110","volume":"17","author":"MS Figueroa","year":"2007","unstructured":"Figueroa MS, Ciancas E, Orte L (2007) Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol 17(1):69\u201374","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"8455_CR8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2007.01.026","volume":"114","author":"AC Hogan","year":"2007","unstructured":"Hogan AC et al (2007) Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114(5):1000\u20131006","journal-title":"Ophthalmology"},{"issue":"3","key":"8455_CR9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0161-6420(96)30683-0","volume":"103","author":"AT Vitale","year":"1996","unstructured":"Vitale AT, Rodriguez A, Foster CS (1996) Low-dose cyclosporin a therapy in treating chronic, noninfectious uveitis. Ophthalmology 103(3):365\u2013373, discussion 373\u20134","journal-title":"Ophthalmology"},{"issue":"5","key":"8455_CR10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","volume":"113","author":"P Kahn","year":"2006","unstructured":"Kahn P et al (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113(5):860\u2013864, e2","journal-title":"Ophthalmology"},{"issue":"5","key":"8455_CR11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00296-003-0308-1","volume":"23","author":"H Mangge","year":"2003","unstructured":"Mangge H et al (2003) Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int 23(5):258\u2013261","journal-title":"Rheumatol Int"},{"issue":"2","key":"8455_CR12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","volume":"113","author":"RT Rajaraman","year":"2006","unstructured":"Rajaraman RT et al (2006) Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113(2):308\u2013314","journal-title":"Ophthalmology"},{"issue":"5","key":"8455_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1442-9071.2005.01062.x","volume":"33","author":"JC Richards","year":"2005","unstructured":"Richards JC et al (2005) Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 33(5):461\u2013468","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"8455_CR14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/ard.2006.065441","volume":"66","author":"SM Sharma","year":"2007","unstructured":"Sharma SM et al (2007) Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis 66(6):840\u2013841","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8455_CR15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.20404","volume":"63","author":"G Simonini","year":"2011","unstructured":"Simonini G et al (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 63(4):612\u2013618","journal-title":"Arthritis Care Res"},{"issue":"4","key":"8455_CR16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","volume":"66","author":"P Tynjala","year":"2007","unstructured":"Tynjala P et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66(4):548\u2013550","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8455_CR17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.120583","volume":"40","author":"ME Zannin","year":"2013","unstructured":"Zannin ME et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry. J Rheumatol 40(1):74\u201379","journal-title":"J Rheumatol"},{"issue":"8","key":"8455_CR18","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447\u20132451","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8455_CR19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10384-012-0202-z","volume":"57","author":"J Matsuda","year":"2013","unstructured":"Matsuda J et al (2013) Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Jpn J Ophthalmol 57(1):104\u2013107","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"8455_CR20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3109\/09273948.2010.496914","volume":"18","author":"M Papadia","year":"2010","unstructured":"Papadia M, Herbort CP (2010) Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis. Ocul Immunol Inflamm 18(6):482\u2013484","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"8455_CR21","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1111\/j.1572-0241.2008.01982_12.x","volume":"103","author":"MR Ally","year":"2008","unstructured":"Ally MR, Veerappan GR, Koff JM (2008) Treatment of recurrent Crohn\u2019s uveitis with infliximab. Am J Gastroenterol 103(8):2150\u20132151","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"8455_CR22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1572-0241.2002.05514.x","volume":"97","author":"W Fries","year":"2002","unstructured":"Fries W et al (2002) Treatment of acute uveitis associated with Crohn\u2019s disease and sacroileitis with infliximab. Am J Gastroenterol 97(2):499\u2013500","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"8455_CR23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","volume":"19","author":"JM Benitez-del-Castillo","year":"2005","unstructured":"Benitez-del-Castillo JM et al (2005) Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond) 19(8):841\u2013845","journal-title":"Eye (Lond)"},{"issue":"6","key":"8455_CR24","first-page":"819","volume":"127","author":"EB Suhler","year":"2009","unstructured":"Suhler EB et al (2009) Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 127(6):819\u2013822","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"8455_CR25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB et al (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123(7):903\u2013912","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"8455_CR26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","volume":"121","author":"JN Kruh","year":"2014","unstructured":"Kruh JN et al (2014) Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology 121(1):358\u2013364","journal-title":"Ophthalmology"},{"issue":"4","key":"8455_CR27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","volume":"149","author":"LB Vazquez-Cobian","year":"2006","unstructured":"Vazquez-Cobian LB, Flynn T, Lehman TJ (2006) Adalimumab therapy for childhood uveitis. J Pediatr 149(4):572\u2013575","journal-title":"J Pediatr"},{"issue":"3","key":"8455_CR28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","volume":"47","author":"P Tynjala","year":"2008","unstructured":"Tynjala P et al (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47(3):339\u2013344","journal-title":"Rheumatology (Oxford)"},{"key":"8455_CR29","doi-asserted-by":"crossref","unstructured":"Turel Ermertcan, A., et al., Psoriatic uveitis responding to adalimumab therapy. Int J Dermatol, 2013.","DOI":"10.1111\/ijd.12194"},{"issue":"2","key":"8455_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","volume":"31","author":"K Takase","year":"2011","unstructured":"Takase K et al (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int 31(2):243\u2013245","journal-title":"Rheumatol Int"},{"issue":"4","key":"8455_CR31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","volume":"97","author":"EB Suhler","year":"2013","unstructured":"Suhler EB et al (2013) Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 97(4):481\u2013486","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"8455_CR32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jcrs.2012.02.026","volume":"38","author":"M Soheilian","year":"2012","unstructured":"Soheilian M et al (2012) Bilateral uveitis after phakic intraocular lens implantation and management with adalimumab. J Cataract Refract Surg 38(6):1094\u20131096","journal-title":"J Cataract Refract Surg"},{"issue":"1","key":"8455_CR33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1546-0096-11-16","volume":"11","author":"G Simonini","year":"2013","unstructured":"Simonini G et al (2013) Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 11(1):16","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"8455_CR34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/09273948.2011.623213","volume":"20","author":"P Seve","year":"2012","unstructured":"Seve P et al (2012) Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm 20(1):59\u201360","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"8455_CR35","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/kes212","volume":"51","author":"ES Sen","year":"2012","unstructured":"Sen ES et al (2012) Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease\u2014a case cohort interventional study. Rheumatology (Oxford) 51(12):2199\u20132203","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"8455_CR36","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696\u2013701","journal-title":"Ann Rheum Dis"},{"key":"8455_CR37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","volume":"15","author":"AV Ramanan","year":"2014","unstructured":"Ramanan AV et al (2014) A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 15:14","journal-title":"Trials"},{"issue":"6","key":"8455_CR38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"B Mushtaq","year":"2007","unstructured":"Mushtaq B et al (2007) Adalimumab for sight-threatening uveitis in Behcet\u2019s disease. Eye (Lond) 21(6):824\u2013825","journal-title":"Eye (Lond)"},{"issue":"1","key":"8455_CR39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/09273948.2011.633205","volume":"20","author":"JN Martel","year":"2012","unstructured":"Martel JN et al (2012) Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm 20(1):18\u201326","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"8455_CR40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/bjo.2006.108050","volume":"91","author":"AM Mansour","year":"2007","unstructured":"Mansour AM (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91(3):274\u2013276","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"8455_CR41","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00417-013-2275-x","volume":"251","author":"A Magli","year":"2013","unstructured":"Magli A et al (2013) Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 251(6):1601\u20131606","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"8455_CR42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/09273948.2010.495814","volume":"18","author":"SY Li","year":"2010","unstructured":"Li SY, Birnbaum AD, Goldstein DA (2010) Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 18(6):475\u2013481","journal-title":"Ocul Immunol Inflamm"},{"issue":"4 Suppl 67","key":"8455_CR43","first-page":"S93","volume":"29","author":"P Leccese","year":"2011","unstructured":"Leccese P et al (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet\u2019s disease to infliximab. Clin Exp Rheumatol 29(4 Suppl 67):S93","journal-title":"Clin Exp Rheumatol"},{"key":"8455_CR44","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/OPTH.S23646","volume":"5","author":"K Kotaniemi","year":"2011","unstructured":"Kotaniemi K, Saila H, Kautiainen H (2011) Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 5:1425\u20131429","journal-title":"Clin Ophthalmol"},{"key":"8455_CR45","doi-asserted-by":"crossref","first-page":"560632","DOI":"10.1155\/2013\/560632","volume":"2013","author":"C Garcia-De-Vicuna","year":"2013","unstructured":"Garcia-De-Vicuna C et al (2013) Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm 2013:560632","journal-title":"Mediat Inflamm"},{"issue":"5","key":"8455_CR46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","volume":"250","author":"RJ Erckens","year":"2012","unstructured":"Erckens RJ et al (2012) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 250(5):713\u2013720","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"8455_CR47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","volume":"97","author":"BC Dobner","year":"2013","unstructured":"Dobner BC et al (2013) A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol 97(2):134\u2013138","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"8455_CR48","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","volume":"119","author":"M Diaz-Llopis","year":"2012","unstructured":"Diaz-Llopis M et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119(8):1575\u20131581","journal-title":"Ophthalmology"},{"issue":"3","key":"8455_CR49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","volume":"24","author":"M Diaz-Llopis","year":"2008","unstructured":"Diaz-Llopis M et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351\u2013361","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"8455_CR50","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/09273948.2013.770888","volume":"21","author":"M Cordero-Coma","year":"2013","unstructured":"Cordero-Coma M et al (2013) Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses. Ocul Immunol Inflamm 21(3):212\u2013219","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"8455_CR51","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/jop.2008.0073","volume":"24","author":"JL Callejas-Rubio","year":"2008","unstructured":"Callejas-Rubio JL et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(6):613\u2013614, author reply 614","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"8455_CR52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/eye.2011.320","volume":"26","author":"S Calleja","year":"2012","unstructured":"Calleja S et al (2012) Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(\u2212) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye (Lond) 26(3):468\u2013477","journal-title":"Eye (Lond)"},{"issue":"5","key":"8455_CR53","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaapos.2013.06.009","volume":"17","author":"L Bravo-Ljubetic","year":"2013","unstructured":"Bravo-Ljubetic L et al (2013) Adalimumab therapy for refractory childhood uveitis. J AAPOS 17(5):456\u2013459","journal-title":"J AAPOS"},{"issue":"3","key":"8455_CR54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","volume":"91","author":"S Biester","year":"2007","unstructured":"Biester S et al (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91(3):319\u2013324","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"8455_CR55","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2009.12.011","volume":"117","author":"S Androudi","year":"2010","unstructured":"Androudi S et al (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117(8):1612\u20131616","journal-title":"Ophthalmology"},{"issue":"4","key":"8455_CR56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12348-012-0081-y","volume":"2","author":"M William","year":"2012","unstructured":"William M et al (2012) Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2(4):231\u2013233","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"8455_CR57","doi-asserted-by":"crossref","unstructured":"Miserocchi, E., et al., Long-term Treatment with Golimumab for Severe Uveitis. Ocul Immunol Inflamm, 2013.","DOI":"10.3109\/09273948.2013.844265"},{"issue":"2","key":"8455_CR58","first-page":"320","volume":"31","author":"E Miserocchi","year":"2013","unstructured":"Miserocchi E et al (2013) Golimumab treatment for complicated uveitis. Clin Exp Rheumatol 31(2):320\u2013321","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"8455_CR59","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","volume":"21","author":"M Mesquida","year":"2013","unstructured":"Mesquida M et al (2013) Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 21(2):160\u2013162","journal-title":"Ocul Immunol Inflamm"},{"key":"8455_CR60","doi-asserted-by":"crossref","unstructured":"Faez, S., et al., Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Experiment Ophthalmol, 2013.","DOI":"10.1111\/ceo.12207"},{"issue":"9","key":"8455_CR61","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.ophtha.2011.05.019","volume":"118","author":"M Cordero-Coma","year":"2011","unstructured":"Cordero-Coma M et al (2011) Golimumab for uveitis. Ophthalmology 118(9):e3\u2013e4, 1892","journal-title":"Ophthalmology"},{"issue":"6","key":"8455_CR62","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","volume":"44","author":"A Reiff","year":"2001","unstructured":"Reiff A et al (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44(6):1411\u20131415","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8455_CR63","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00124743-200106000-00008","volume":"7","author":"BJ Smith","year":"2001","unstructured":"Smith BJ, McMillan VM, Newton JS (2001) Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy. J Clin Rheumatol 7(3):175\u2013178","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"8455_CR64","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","volume":"121","author":"CS Foster","year":"2003","unstructured":"Foster CS et al (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121(4):437\u2013440","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"8455_CR65","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","volume":"44","author":"H Schmeling","year":"2005","unstructured":"Schmeling H, Horneff G (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 44(8):1008\u20131011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8455_CR66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","volume":"53","author":"JA Smith","year":"2005","unstructured":"Smith JA et al (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53(1):18\u201323","journal-title":"Arthritis Rheum"},{"issue":"10","key":"8455_CR67","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","volume":"56","author":"LL Lim","year":"2007","unstructured":"Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56(10):3248\u20133252","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8455_CR68","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","volume":"69","author":"J Sieper","year":"2010","unstructured":"Sieper J et al (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69(1):226\u2013229","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"8455_CR69","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.2007.075754","volume":"67","author":"N Zeboulon","year":"2008","unstructured":"Zeboulon N, Dougados M, Gossec L (2008) Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 67(7):955\u2013959","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8455_CR70","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H et al (2011) GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol 64(4):401\u2013406","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"8455_CR71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-006-9060-0","volume":"27","author":"TA Waldmann","year":"2007","unstructured":"Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27(1):1\u201318","journal-title":"J Clin Immunol"},{"issue":"13","key":"8455_CR72","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","volume":"96","author":"RB Nussenblatt","year":"1999","unstructured":"Nussenblatt RB et al (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial. Proc Natl Acad Sci U S A 96(13):7462\u20137466","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"8455_CR73","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0896-8411(03)00113-6","volume":"21","author":"RB Nussenblatt","year":"2003","unstructured":"Nussenblatt RB et al (2003) Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21(3):283\u2013293","journal-title":"J Autoimmun"},{"issue":"2","key":"8455_CR74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2008.05.001","volume":"31","author":"S Yeh","year":"2008","unstructured":"Yeh S et al (2008) High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 31(2):91\u201397","journal-title":"J Autoimmun"},{"issue":"5","key":"8455_CR75","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2004.12.034","volume":"112","author":"RB Nussenblatt","year":"2005","unstructured":"Nussenblatt RB et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5):764\u2013770","journal-title":"Ophthalmology"},{"issue":"4","key":"8455_CR76","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jcjo.2011.06.008","volume":"46","author":"K Wroblewski","year":"2011","unstructured":"Wroblewski K et al (2011) Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol 46(4):322\u2013328","journal-title":"Can J Ophthalmol"},{"issue":"5","key":"8455_CR77","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2007.01.010","volume":"119","author":"W Chi","year":"2007","unstructured":"Chi W et al (2007) IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 119(5):1218\u20131224","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"8455_CR78","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick AD et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777\u2013787","journal-title":"Ophthalmology"},{"issue":"4","key":"8455_CR79","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3121\/cmr.4.4.294","volume":"4","author":"KG Ooi","year":"2006","unstructured":"Ooi KG et al (2006) Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin Med Res 4(4):294\u2013309","journal-title":"Clin Med Res"},{"issue":"3 Suppl 77","key":"8455_CR80","first-page":"152","volume":"31","author":"G Emmi","year":"2013","unstructured":"Emmi G et al (2013) Anakinra for resistant Behcet uveitis: why not? Clin Exp Rheumatol 31(3 Suppl 77):152\u2013153","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"8455_CR81","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bjo.2006.0101477","volume":"91","author":"SC Teoh","year":"2007","unstructured":"Teoh SC et al (2007) Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 91(2):263\u2013264","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"8455_CR82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A Gul","year":"2012","unstructured":"Gul A et al (2012) Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: an open-label pilot study. Ann Rheum Dis 71(4):563\u2013566","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8455_CR83","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1076\/ocii.7.2.75.4017","volume":"7","author":"J Petrinovic-Doresic","year":"1999","unstructured":"Petrinovic-Doresic J et al (1999) Interleukin 6 and its soluble receptor are elevated in aqueous humor of patients with uveitis. Ocul Immunol Inflamm 7(2):75\u201384","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"8455_CR84","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","volume":"19","author":"A Muselier","year":"2011","unstructured":"Muselier A et al (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 19(5):382\u2013383","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"8455_CR85","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","volume":"39","author":"C Tappeiner","year":"2012","unstructured":"Tappeiner C et al (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39(6):1294\u20131295","journal-title":"J Rheumatol"},{"issue":"11","key":"8455_CR86","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","volume":"251","author":"A Adan","year":"2013","unstructured":"Adan A et al (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251(11):2627\u20132632","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"8455_CR87","doi-asserted-by":"crossref","unstructured":"Tsang, A.C., J. Roth, and C. Gottlieb, Tocilizumab for Severe Chronic Anterior Uveitis Associated with Juvenile Idiopathic Arthritis in a Pediatric Patient. Ocul Immunol Inflamm, 2013.","DOI":"10.3109\/09273948.2013.866254"},{"issue":"1","key":"8455_CR88","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","volume":"144","author":"J Plskova","year":"2007","unstructured":"Plskova J, Greiner K, Forrester JV (2007) Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144(1):55\u201361","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"8455_CR89","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00417-010-1523-6","volume":"249","author":"N Kenawy","year":"2011","unstructured":"Kenawy N et al (2011) Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 249(2):297\u2013300","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"8455_CR90","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000336188","volume":"51","author":"E Miserocchi","year":"2012","unstructured":"Miserocchi E, Modorati G (2012) Rituximab for noninfectious uveitis. Dev Ophthalmol 51:98\u2013109","journal-title":"Dev Ophthalmol"},{"issue":"1","key":"8455_CR91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ophtha.2010.07.031","volume":"118","author":"E Miserocchi","year":"2011","unstructured":"Miserocchi E et al (2011) Rituximab for uveitis. Ophthalmology 118(1):223\u2013224","journal-title":"Ophthalmology"},{"issue":"6","key":"8455_CR92","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","volume":"62","author":"F Zulian","year":"2010","unstructured":"Zulian F et al (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 62(6):821\u2013825","journal-title":"Arthritis Care Res"},{"issue":"9","key":"8455_CR93","first-page":"1897","volume":"35","author":"S Angeles-Han","year":"2008","unstructured":"Angeles-Han S, Flynn T, Lehman T (2008) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis\u2014a case report. J Rheumatol 35(9):1897\u20131898","journal-title":"J Rheumatol"},{"issue":"2","key":"8455_CR94","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acr.20359","volume":"63","author":"M Elhai","year":"2011","unstructured":"Elhai M, Deslandre CJ, Kahan A (2011) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article By Zulian et al. Arthritis Care Res 63(2):307\u2013308, author reply 308","journal-title":"Arthritis Care Res"},{"issue":"10","key":"8455_CR95","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.ophtha.2008.03.027","volume":"115","author":"JG Parikh","year":"2008","unstructured":"Parikh JG, Tawansy KA, Rao NA (2008) Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology 115(10):1833\u20131836","journal-title":"Ophthalmology"},{"issue":"8","key":"8455_CR96","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","volume":"50","author":"A Heiligenhaus","year":"2011","unstructured":"Heiligenhaus A et al (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 50(8):1390\u20131394","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"8455_CR97","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000103239","volume":"39","author":"C Tappeiner","year":"2007","unstructured":"Tappeiner C et al (2007) Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 39(3):184\u2013186","journal-title":"Ophthalmic Res"},{"issue":"1","key":"8455_CR98","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/jop.2012.0238","volume":"30","author":"E Yuksel","year":"2014","unstructured":"Yuksel E et al (2014) Comparison of acute effect of systemic versus intravitreal infliximab treatment in an experimental model of endotoxin-induced uveitis. J Ocul Pharmacol Ther 30(1):74\u201380","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"8455_CR99","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","volume":"154","author":"N Markomichelakis","year":"2012","unstructured":"Markomichelakis N et al (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534\u2013541, e1","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"8455_CR100","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1177\/112067210901900521","volume":"19","author":"H Hosseini","year":"2009","unstructured":"Hosseini H et al (2009) Intravitreal infliximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol 19(5):818\u2013823","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"8455_CR101","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/jop.2011.0199","volume":"28","author":"M Farvardin","year":"2012","unstructured":"Farvardin M, Afarid M, Shahrzad S (2012) Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther 28(6):628\u2013631","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9","key":"8455_CR102","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/IAE.0b013e3181d3758a","volume":"30","author":"M Farvardin","year":"2010","unstructured":"Farvardin M et al (2010) Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 30(9):1530\u20131535","journal-title":"Retina"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-014-8455-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-014-8455-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-014-8455-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T21:58:49Z","timestamp":1566079129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-014-8455-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,29]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["8455"],"URL":"https:\/\/doi.org\/10.1007\/s12016-014-8455-6","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,29]]}}}